ing, burning, exfoliation, and itching occurred over a range of 1% to 7% in TazF-treated subjects compared to up to 1% in vehicle-treated subjects; similar tolerability outcomes were shown in both genders and across all age groups and races among enrolled subjects. Importantly, study discontinuation occurred in only 2.7% of TazF-treated subjects compared to 0.13% of vehicle-treated subjects. No systemic safety signals were noted.33 Patient Assessments of Characteristics of Aqueous Foam Formulations Subjects in both the two CalcipF phase III studies (n=655) and two TazF phase III studies (n=1396) rated the qualities of their rerespective aqueous foam formulations.41 The results demonstrate that most subjects were highly satisfied with several delivery qualities of both foam vehicles. Figure 6 and Figure 7 show patient survey results of delivery qualities with the calcipotriene aqueous emulsion foam and the tazarotene aqueous foam, respectively. Subjects in both studies who completed these surveys did not know if they were using the active foam or the vehicle foam due to the double-blind methodology used in these pivotal studies.41 The sum effect of these favorable foam delivery characteristics is likely to be improved adherence with treatment among many patients.
